spacer
home > ict > autumn 2009 > cold chain on the global stage
PUBLICATIONS
International Clinical Trials

Cold Chain on the Global Stage

 

Conducting clinical trials accounts for nearly one third of drug development costs, according to a recent report from Frost & Sullivan (1). In fact, the cost per patient of running Phase III clinical studies of new pharmaceuticals now tends to exceed $26,000 (2). One of the major causes of rising R&D costs is that 80 per cent of clinical trials fail to recruit patients on time (3). The migration of clinical trials into emerging markets offers a possible resolution to this issue; however, as with many aspects of drug development, this approach does not come without obstacles. This article will outline logistical issues involved in conducting clinical trials in emerging markets, and highlight measures that pharma and biotech companies can implement to ensure compliant transportation of temperature-sensitive clinical trial samples and supplies on time.

ADVANTAGES OF EMERGING MARKETS

Throughout traditional patient recruiting grounds, such as North America and western Europe, sponsors have historically competed for a limited pool of investigators and patients. Emerging clinical trial regions such as South America, eastern Europe and Asia offer access to large patient populations, the majority of which are treatment-naive. In countries within eastern Europe, sponsors have reported that recruitment rates are five to 10 times higher than in western Europe and the US (4). Furthermore, countries such as Brazil, Mexico and Argentina provide substantial advantages to sponsors conducting clinical trials there. As North and South America share the same Western hemisphere, they also share many of the same prevalent diseases. However, seasonal diseases occur six months out of phase between North America and Europe, giving researchers the ability to conduct year-round seasonal trials, which can significantly reduce development times for seasonal medications (5).

Although these regions provide access to large, treatmentnaive populations, emerging markets present regulatory and logistical challenges for companies conducting clinical trials there. Accordingly, it is paramount that pharmaceutical companies fully understand the complexities of shipping clinical trial samples and supplies to emerging countries. This will ensure any potential benefits are not compromised due to inadequate knowledge and preparation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Global Head of Logistics and Facilities, Jeff Clark oversees BioStorage Technologies’ day-to-day cold chain logistics for the US and Europe. He is responsible for ensuring the integrity of clients’ biological materials throughout all phases of shipping, handling, tracking and storage. In this role, Jeff develops and manages all logistics and customer service processes, defines requirements for the company’s proprietary sample management system, and negotiates global transportation and logistics partnerships. Jeff holds a diploma from the International Air Transport Association (IATA) and International Federation of Freight Forwarders Association (FIATA). He also earned certifications in international rates and tariffs, advanced cargo agent 803-53/01 and IATA hazmat training, and is a member of the American Chemical Council.
spacer
Jeff Clark
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement